In conclusion, based on the partitioned survival analysis, this study found that while ribociclib provides significant survival benefits, it does not appear to be cost-effective when compared to endocrine therapy alone in treating pre/perimenopausal women with HR+/HER2- advanced breast cancer with a WTP of $150,000/QALY. This evidence concerns the gene HR and breast cancer.